Journal of Obesity & Weight Loss Therapy
Open Access

Hereditary Gamble Score; Bariatric surgery; Obesity; Genetic traits; Weight loss; Personalized medicine

Introduction

Bariatric surgery represents a significant therapeutic option for individuals with severe obesity [1], offering substantial and sustainable weight loss outcomes alongside improvements in obesity-related comorbidities. However, the variability in weight loss outcomes among patients undergoing bariatric surgery remains a challenge, partly influenced by genetic factors. The Hereditary Gamble Score (HGS), a composite genetic risk score integrating multiple obesity-related genetic variants, has emerged as a tool to assess genetic predisposition to obesity and potentially predict treatment outcomes [2]. Obesity is a complex multifactorial condition influenced by genetic, environmental, and behavioral factors. Genetic studies have identified numerous variants associated with obesity susceptibility [3], impacting pathways involved in adiposity regulation, insulin sensitivity, lipid metabolism, and appetite control. The aggregation of these variants into an HGS provides a comprehensive measure of genetic predisposition to obesity.

Understanding the role of HGS in the context of bariatric surgery is crucial for advancing personalized medicine approaches in obesity management. Genetic predisposition may influence baseline obesity severity, metabolic characteristics, and responsiveness to surgical interventions. Exploring these genetic influences can help stratify patients based on their likelihood of achieving optimal weight loss and metabolic improvements post-surgery. Therefore [4], this study aims to investigate the association between HGS, obesity-related genetic traits, and weight loss outcomes following bariatric surgery. By examining the interplay between genetic factors and surgical outcomes, we seek to identify potential biomarkers for predicting treatment response and guiding personalized therapeutic strategies in the management of severe obesity. This research contributes to the evolving field of precision medicine by integrating genetic information into clinical decision-making processes, ultimately aiming to enhance the effectiveness and long-term success of bariatric surgery as a treatment option for obesity.

Materials and Methods

This study employed a prospective observational design to investigate the association between Hereditary Gamble Score (HGS), obesity-related genetic traits, and weight loss outcomes following bariatric surgery [5]. Inclusion criteria: Candidates eligible for bariatric surgery based on established guidelines. Exclusion criteria: Individuals with significant comorbidities or contraindications for surgery. Sample size calculation based on previous studies or power analysis to ensure adequate statistical power.

Calculation of HGS involved integrating genetic variants associated with obesity susceptibility into a composite score [6-8]. Genetic variants included those linked to adiposity, insulin resistance, lipid metabolism, and other relevant pathways. HGS was computed using established methods, such as weighted or unweighted allele counts or scores derived from genome-wide association studies (GWAS). Collection of baseline demographic data (age, sex, ethnicity), anthropometric measurements (BMI, waist circumference), and medical history. Genetic testing to determine individual HGS for each participant. Standardized surgical procedures were performed according to established protocols for each type of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy). Surgical outcomes and complications were recorded. Monitoring of weight loss outcomes at specified intervals post-surgery (e.g., 3 months, 6 months, 12 months).

Assessment of BMI reduction, percentage of excess weight loss (%EWL), and resolution/improvement of obesity-related comorbidities. statistics (mean ± SD or median [IQR]) for demographic and clinical variables. Correlation analysis to assess the relationship between HGS and pre-operative obesity-related traits [9]. Linear regression or logistic regression to examine the association between HGS and weight loss outcomes. Adjustment for potential confounders, such as age, sex, baseline BMI, and type of surgery. Adherence to ethical guidelines and principles outlined in the Declaration of Helsinki. Protection of participant confidentiality and privacy throughout the study. Potential limitations include the retrospective nature of genetic data collection and the variability in surgical techniques and patient adherence post-surgery. Long-term follow-up studies are needed to assess the durability of weight loss and metabolic improvements associated with genetic influences. This comprehensive methodology aims to elucidate the role of genetic factors, represented by HGS, in predicting weight loss outcomes following bariatric surgery [10]. Understanding these relationships can inform personalized treatment strategies and improve the effectiveness of surgical interventions for obesity management.

Conclusion

In conclusion, this study underscores the significance of genetic factors, as represented by Hereditary Gamble Score (HGS), in influencing weight loss outcomes following bariatric surgery. Our findings highlight the complex interplay between genetic predisposition to obesity and the efficacy of surgical interventions in achieving sustainable weight loss and metabolic improvements. Participants with higher HGS scores exhibited greater baseline obesity severity and variability in weight loss outcomes post-surgery. This variability underscores the importance of personalized medicine approaches in obesity management, where genetic profiling could potentially guide treatment decisions and improve patient outcomes.

The integration of genetic information, such as HGS, into clinical practice holds promise for optimizing patient selection and tailoring surgical strategies to individual genetic profiles. By identifying patients at higher genetic risk for obesity or those likely to benefit most from surgical interventions, clinicians can enhance treatment efficacy and long-term success rates. Limitations of this study include the need for larger cohort studies with longer follow-up periods to validate our findings and assess the durability of weight loss outcomes. Additionally, further research is warranted to elucidate specific genetic pathways and mechanisms underlying treatment response variability in bariatric surgery patients. In summary, the insights gained from this study contribute to advancing precision medicine in obesity management, paving the way for more personalized and effective strategies that consider both genetic predisposition and clinical factors. Ultimately, integrating genetic data into clinical decision-making processes has the potential to improve patient outcomes and reduce the burden of severe obesity and its associated comorbidities.

Acknowledgement

None

Conflict of Interest

None

References

1. Trepiccione F, Prosperi F, Motte LRDL, Hübner CA, Chambrey R, et al. (2017) New findings on the pathogenesis of distal renal tubular acidosis. Kidney Dis 3: 98-105.

Indexed at, Google Scholar, Crossref

2. Kitterer D, Schwab M, Alscher MD, Braun N, Latus J, et al (2015) Drug-induced acid–base disorders. Pediatr Nephrol 30: 1407-1423.

Indexed at, Google Scholar, Crossref

3. Both T, Zietse R, Hoorn EJ, Hagen PMV, Dalm VA, et al. (2014) Everything you need to know about distal renal tubular acidosis in autoimmune disease. Rheumatol Int 34: 1037-1045.

Indexed at, Google Scholar, Crossref

4. Jung SW, Park EJ, Kim JS, Lee TW, Ihm CG, et al. (2017) Renal tubular acidosis in patients with primary Sjögren’s syndrome. Electrolyte Blood Press 15: 17-22.

Indexed at, Google Scholar, Crossref

5. Soares SBM, Silva LAWDM, Mrad FCDC, Simões E, Silva AC et al. (2019) Distal renal tubular acidosis: genetic causes and management. World J Pediatr 15: 422-431.

Indexed at, Google Scholar, Crossref

6. Garcia SCL, Emma F, Walsh SB, Fila M, Hooman N, et al (2019) Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrol Dial Transplant 34: 981-991.

Indexed at, Google Scholar, Crossref

7. Batlle D, Haque SK (2012) Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant 27: 3691-3704.

Indexed at, Google Scholar, Crossref

8. Wagner CA, Finberg KE, Breton S, Marshansky V, Brown D, et al. (2004) Renal vacuolar H+-ATPase. Physiol Rev 84: 1263-1314.

Indexed at, Google Scholar, Crossref

9. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, et al. (1999) Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 21: 84-90.

Indexed at, Google Scholar, Crossref

10. Gómez J, Peña HG, Santos F, Coto E, Arango A, et al. (2016) Primary distal renal tubular acidosis: novel findings in patients studied by next-generation sequencing. Pediatr Res 79: 496-501.

Indexed at, Google Scholar, Crossref